Novo Acquires Three Non-Incretin Obesity Programs from Kallyope to Diversify Pipeline

Key points

• Novo acquired three obesity programs from Kallyope, including a first-in-class peptide, a small molecule follow-on, and a receptor agonist, all non-incretin based.
• The lead candidate, K-554, is IND-ready and designed as a once-weekly treatment to regulate food intake via novel biology, with Phase 1 data expected in the second half of 2026.
• The acquisition follows Novo’s recent rebranding and a $1.4 billion deal with Orbis Medicines for cardiometabolic macrocycle drugs, signaling a broader strategic push beyond GLP-1s.
• Novo is not disclosing financial terms or specific drug targets for the Kallyope deal, though it aims to strengthen its pipeline with externally sourced science.
• The move occurs amid pipeline setbacks, including the discontinuation of phase 3 trials for ziltivekimab, a cardiovascular drug that had projected peak sales of $3 billion.

Background

This acquisition follows Novo’s September 2026 rebranding from Novo Nordisk to Novo, part of a cultural overhaul to regain momentum in the obesity drug market against Eli Lilly. The company has been expanding its pipeline beyond GLP-1s, including a recent $1.4 billion deal with Orbis Medicines for cardiometabolic targets. Meanwhile, Novo faced setbacks with ziltivekimab, a cardiovascular drug that failed in multiple phase 3 trials, highlighting the need for diversified pipeline strategies. Earlier studies also suggested GLP-1 drugs might benefit PMOS patients, though insurance coverage remains a barrier.

Why it matters

Novo’s acquisition of non-incretin obesity programs signals a strategic pivot to diversify its pipeline beyond GLP-1s, addressing competition from Eli Lilly and mitigating risks from recent drug failures. The move underscores the industry’s push for novel mechanisms to treat obesity, potentially expanding treatment options for patients who do not respond to incretin-based therapies. This diversification could strengthen Novo’s long-term market position and reduce reliance on a single drug class.

What to watch

Novo expects Phase 1 data for K-554 in the second half of 2026, with multiple candidates entering clinical development this year. The company will likely provide further details on the Kallyope deal’s financial terms and drug targets as development progresses. Additionally, Novo’s broader pipeline expansion, including the Orbis Medicines deal, will shape its competitive stance in the obesity and cardiometabolic markets.